- Coordinator
- Invitris, Germany
- Runs
- 1 July 2025 to 30 June 2027
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101218038
What the project is doing
In the project's own words, from its summary on CORDIS.
The rise of drug-resistant bacteria necessitates the development of alternative therapies that can specifically target and eliminate these pathogens while minimizing harm to the patient's microbiome. Bacteriophages (phages) are potent therapeutics that can fight multidrugresistant pathogenic bacteria. Unlike broad-spectrum antibiotics, phages can selectively eliminate bacteria. However, the current production processes for phages pose considerable biosafety concerns and are often relatively inefficient, unreliable, and unscalable.
Invitris has fundamentally transformed the way phages can be developed with its unique in vitro platform technology, Phactory™. For the first time, Phactory™ enables scalable, personalized production and rapid engineering of novel drugs based on phages. We aim to leverage the support by EIC to standardize the clinical production process of Phactory™ and conduct clinical trials to validate the efficacy and safety of novel phage-based therapies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Invitris | Planegg-Martinsried | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI